Monopar Therapeutics Inc. Share Price
MNPRMonopar Therapeutics Inc. Stock Performance
Open $60.53 | Prev. Close $60.96 | Circuit Range N/A |
Day Range $59.05 - $62.23 | Year Range $29.22 - $103.77 | Volume 5,307 |
Average Traded $60.76 |
Monopar Therapeutics Inc. Share Price Chart
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
09-Jun-26 | $60.53 | $60.00 | +0.00% |
09-Jun-26 | $60.53 | $60.00 | -1.57% |
08-Jun-26 | $60.92 | $60.96 | +2.32% |
05-Jun-26 | $59.26 | $59.58 | -0.18% |
04-Jun-26 | $60.90 | $59.69 | -1.53% |
03-Jun-26 | $59.08 | $60.62 | -2.30% |
02-Jun-26 | $62.27 | $62.05 | -3.57% |